Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer

The Oncologist(2022)10.1093/oncolo/oyac025Source: DataRank Database

Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer is a research paper published in The Oncologist (2022). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 2.14)OA: goldTopics (47)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (27)

Michael R. Marco ORCID,Campbell S.D. Roxburgh ORCID,Chin‐Tung Chen ORCID,Andrea Cercek ORCID,Paul Strombom ORCID

Live enrichment

PubMed:35278070 PMC:PMC9074984 OpenAlex:https://openalex.org/W4210323318

National Institutes of Health

Grant: P30 CA008748

National Institutes of Health

Grant: T32CA009501

NCI NIH HHS

Grant: K08 CA255574

Chief Scientist Office

Grant: SCAF/19/01

AHRQ HHS

Grant: T32 HS000063

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 5T32CA009501-22

SURGICAL ONCOLOGY RESEARCH TRAINING GRANT

FWCI

2.14

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://academic.oup.com/oncolo/article-pdf/27/5/380/43590644/oyac025.pdf

publisherhttps://academic.oup.com/oncolo/article-pdf/27/5/380/43590644/oyac025.pdf

journalhttps://doi.org/10.1093/oncolo/oyac025

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35278070

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9074984

Fields of Study

Colorectal Cancer Surgical TreatmentsColorectal and Anal CarcinomasEsophageal Cancer Research and Treatment03 medical and health sciences0302 clinical medicine

MeSH Terms

Antineoplastic Combined Chemotherapy ProtocolsHumansNeoplasm StagingRectal NeoplasmsRectumRetrospective StudiesNeoplasms, Second PrimaryChemotherapy, AdjuvantDisease-Free SurvivalNeoadjuvant TherapyChemoradiotherapyInduction Chemotherapy

Keywords

MedicineColorectal cancerOxaliplatinChemoradiotherapyNeoadjuvant therapyOncologyInternal medicineHazard ratioTotal mesorectal excisionInduction chemotherapyChemotherapyFluorouracilSurgeryConfidence intervalCancerBreast cancerSurvivalResponseLocally Advanced Rectal CancerTotal Neoadjuvant TherapyRectal NeoplasmsRectumNeoplasms, Second PrimaryDisease-Free SurvivalChemotherapy, AdjuvantGastrointestinal CancerAntineoplastic Combined Chemotherapy ProtocolsHumansNeoplasm StagingRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being